By 15 months of follow-up, patients in the BNP-guided treatment group had a significantly lower number of events of HF-related death or readmission than the patients treated according to current guidelines (24% vs. 52%, p < 0.001) [55]. This evidence concerns the gene NPPB and hydrops fetalis.